Regulatory UpdatesAug 30, 2026•1 min read

Claudin18.2‑Targeted CAR‑T Therapy Achieves First Global Approval for Solid Tumor

By the PharmaCountry team

Claudin18.2‑targeted CAR‑T therapy is the first CAR‑T to receive global approval for a solid tumor.

A CAR‑T therapy targeting Claudin18.2 has secured global regulatory approval. It is the first CAR‑T approved for a solid tumor.

Compiled by the PharmaCountry team · Source: FiercePharma

Ratings

(0)